Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
Ashokraj
Y
Y
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India.
Agrawal
S
S
Varma
M V S
MV
Singh
I
I
Gunjan
K
K
Kaur
K J
KJ
Bhade
S R
SR
Kaul
C L
CL
Caudron
J M
JM
Pinel
J
J
Panchagnula
R
R
D000904:Antibiotics, Antitubercular / Q000737:chemistry / Q000493:pharmacokinetics / Q000592:standards*; D000995:Antitubercular Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000592:standards*; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D004345:Drug Industry; D004359:Drug Therapy, Combination; D014943:Global Health; D006801:Humans; D019064:Product Packaging; D011786:Quality Control; D012293:Rifampin / Q000737:chemistry / Q000493:pharmacokinetics / Q000592:standards*; D012995:Solubility; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D012293:Rifampin